|
DBV Technologies
25 Deforest Avenue, Suite 203 Summit, NJ 07901 www.dbv-technologies.com About DBV Technologies DBV Technologies is a global biopharmaceutical company that’s developing investigational epicutaneous immunotherapy (EPIT™) technology to treat millions of people suffering from life-threatening food allergies and other immunological disorders. Starting with peanut, we are investigating food allergy treatments that are designed to potentially reduce the risk of unpredictable, life-threatening reactions due to accidental exposure. Representative Joseph M Chalil, MD, MBA, FACHE Senior Director, Clinical Development & Medical Affairs joseph.chalil@dbv-technologies.com Jeff Germani Director, Clinical Development & Medical Affairs jeff.germani@dbv-technologies.com Todd D. Green, MD, FAAAAI, FACAAI Vice President, Clinical Development & Medical Affairs todd.green@dbv-technologies.com Katharine Bee, PhD Senior Director, Medical Services & Communications katharine.bee@dbv-technologies.com Social Media https://twitter.com/dbvtechnologies https://www.linkedin.com/company/dbv-technologies https://www.facebook.com/DBVTechnologies/ |
Representatives will be available to meet with attendees at the following times:
|
